Ultragenyx Pharmaceutical Inc.
RARE | NASDAQ
$15.55
+$0.90 (+6.14%)
Sep 22, 2026, 11:21 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 673M | 560.23M | 434.25M | 363.33M | 351.41M | 271.03M |
Cost of Revenue | 109M | 76.73M | 45.21M | 28.32M | 16.01M | 6.13M |
Gross Profit | 564M | 483.5M | 389.04M | 335.01M | 335.4M | 264.9M |
Operating Income | -535M | -535.97M | -569.21M | -648.92M | -381.74M | -330.12M |
Interest Income | 25M | 36.51M | 26.69M | 11.07M | 1.93M | 7.04M |
Pretax Income | -571M | -567.59M | -608.46M | -701.73M | -452.98M | -185.36M |
Net Income | -575M | -569.18M | -606.64M | -707.42M | -454.03M | -186.57M |
Selling & General & Admin | 349M | 321.61M | 309.8M | 278.14M | 219.98M | 182.93M |
Research & Development | 750M | 697.87M | 648.45M | 705.79M | 497.15M | 412.08M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.1B | 1.02B | 958.25M | 983.93M | 717.14M | 595.02M |
Interest Expense | 62M | 63.04M | 66M | 43.02M | 29.42M | 33.29M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.21B | 1.1B | 1B | 1.01B | 733.14M | 601.15M |
Income Tax Expense | 4M | 1.6M | -1.83M | 5.7M | 1.04M | 1.21M |
Shares Outstanding (Basic) | 98.6M | 90.54M | 73.54M | 69.91M | 67.8M | 60.85M |
Shares Outstanding (Diluted) | 98.6M | 90.54M | 73.54M | 69.91M | 67.8M | 60.85M |
EPS (Basic) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
EPS (Diluted) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
EBITDA | -474M | -469M | -516.45M | -640.49M | -410.32M | -139.81M |
EBIT | -509M | -504.55M | -542.46M | -658.71M | -423.56M | -152.07M |
Depreciation & Amortization | 35M | 35.54M | 26.01M | 18.22M | 13.24M | 12.26M |
Add to Watchlist
Select watchlists to add or remove RARE